Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Public ClinicalTrials.gov record NCT00099437. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Fulvestrant (FASLODEX™) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy
Study identification
- NCT ID
- NCT00099437
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 736 participants
Conditions and interventions
Conditions
Interventions
- Fulvestrant Drug
Drug
Eligibility (public fields only)
- Age range
- 45 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2005
- Primary completion
- Feb 26, 2009
- Completion
- Dec 30, 2026
- Last update posted
- Jun 10, 2026
2005 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Casa Grande | Arizona | 85122 | — |
| Research Site | Fountain Valley | California | 92708 | — |
| Research Site | New Britain | Connecticut | 06052 | — |
| Research Site | Crystal River | Florida | 34429 | — |
| Research Site | Fort Lauderdale | Florida | 33308 | — |
| Research Site | Urbana | Illinois | 61801 | — |
| Research Site | Rosedale | Maryland | 21237 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Kansas City | Missouri | 64131 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | Voorhees Township | New Jersey | 08043 | — |
| Research Site | Greenville | North Carolina | 27858 | — |
| Research Site | Pasadena | Texas | 77504 | — |
| Research Site | West Bend | Wisconsin | 53095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 92 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00099437, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00099437 live on ClinicalTrials.gov.